1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 Group of Eight (G8) Generics
2.1. Industry Outlook
3 Generics in Canada
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
4 Macroeconomic Indicators
4.1. Country data
5 Generics in France
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
6 Macroeconomic Indicators
6.1. Country data
7 Generics in Germany
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
8 Macroeconomic Indicators
8.1. Country data
9 Generics in Italy
9.1. Market Overview
9.2. Market Data
9.3. Market Segmentation
9.4. Market outlook
9.5. Five forces analysis
10 Macroeconomic Indicators
10.1. Country data
11 Generics in Japan
11.1. Market Overview
11.2. Market Data
11.3. Market Segmentation
11.4. Market outlook
11.5. Five forces analysis
12 Macroeconomic Indicators
12.1. Country data
13 Generics in Russia
13.1. Market Overview
13.2. Market Data
13.3. Market Segmentation
13.4. Market outlook
13.5. Five forces analysis
14 Macroeconomic Indicators
14.1. Country data
15 Generics in The United Kingdom
15.1. Market Overview
15.2. Market Data
15.3. Market Segmentation
15.4. Market outlook
15.5. Five forces analysis
16 Macroeconomic Indicators
16.1. Country data
17 Generics in The United States
17.1. Market Overview
17.2. Market Data
17.3. Market Segmentation
17.4. Market outlook
17.5. Five forces analysis
18 Macroeconomic Indicators
18.1. Country data
19 Company Profiles
19.1. Sun Pharmaceutical Industries Ltd
19.2. Viatris Inc
19.3. Novartis AG
19.4. Teva Pharmaceutical Industries Ltd
19.5. Sandoz Group AG
19.6. Hikma Pharmaceuticals Plc
19.7. Sanofi
19.8. Les Laboratoires Servier SAS
19.9. Stada Arzneimittel AG
19.10. Bayer AG
19.11. Lupin Ltd
19.12. Aspen Pharmacare Holdings Ltd
19.13. EMS SA
19.14. Eurofarma Laboratorios SA
19.15. Ache Laboratorios Farmaceuticos SA
19.16. Sino Biopharmaceutical Ltd
19.17. Hansoh Pharmaceutical Group Co Ltd
19.18. CSPC Pharmaceutical Group Ltd
19.19. Dr. Reddy's Laboratories Ltd
19.20. Cipla Ltd
19.21. Aurobindo Pharma Ltd
19.22. PT Indofarma Tbk
19.23. PT Sanbe Farma
19.24. PT Kalbe Farma Tbk
19.25. PT Soho Global Health Tbk
19.26. Friulchem SpA
19.27. DOC Generici SRL
19.28. Recordati SpA
19.29. Daiichi Sankyo Co Ltd
19.30. Sawai Group Holdings Co Ltd
19.31. Toho Holdings Co Ltd
19.32. Towa Pharmaceutical Co Ltd
19.33. Laboratorios Silanes SA de CV
19.34. Pfizer Inc
19.35. Bluefish Pharmaceuticals AB
19.36. AstraZeneca Plc
19.37. Navamedic ASA
19.38. Beacons Pharmaceuticals Pte Ltd
19.39. Abbott Laboratories SA
19.40. Adcock Ingram Holdings Ltd
19.41. Dongkook Pharmaceutical Co Ltd
19.42. JW Holdings Corp
19.43. Hanmi Pharmaceuticals Co Ltd
19.44. Dong Wha Pharma Co Ltd
19.45. Esteve Pharmaceuticals SA
19.46. Abdi Ibrahim Ilac Sanayi ve Ticaret AS
19.47. Deva Holding AS
19.48. Apotex Inc
19.49. Pharmstandard
19.50. Biocad
19.51. R-Pharm
20 Appendix
20.1. Methodology
20.2. About the Publisher
List of Tables
Table 1: G8 generics industry, revenue($m), 2020-29
Table 2: G8 generics industry, revenue by country ($m), 2020-24
Table 3: G8 generics industry forecast, revenue by country ($m), 2024-29
Table 4: Canada generics market value: $ million, 2019-24
Table 5: Canada generics market volume: % of total pharma volume, 2019-24
Table 6: Canada generics market geography segmentation: $ million, 2024
Table 7: Canada generics market value forecast: $ million, 2024-29
Table 8: Canada generics market volume forecast: % of total pharma volume, 2024-29
Table 9: Canada Size of Population (Million), 2020-24
Table 10: Canada Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 11: Canada GDP (Current Prices, $ Billion), 2020-24
Table 12: Canada Inflation, 2020-24
Table 13: Canada Consumer Price Index (Absolute), 2020-24
Table 14: Canada Exchange Rate, 2019-24
Table 15: France generics market value: $ million, 2019-24
Table 16: France generics market volume: % of total pharma volume, 2019-24
Table 17: France generics market geography segmentation: $ million, 2024
Table 18: France generics market value forecast: $ million, 2024-29
Table 19: France generics market volume forecast: % of total pharma volume, 2024-29
Table 20: France Size of Population (Million), 2020-24
Table 21: France Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 22: France GDP (Current Prices, $ Billion), 2020-24
Table 23: France Inflation, 2020-24
Table 24: France Consumer Price Index (Absolute), 2020-24
Table 25: France Exchange Rate, 2019-24
Table 26: Germany generics market value: $ million, 2019-24
Table 27: Germany generics market volume: % of total pharma volume, 2019-24
Table 28: Germany generics market geography segmentation: $ million, 2024
Table 29: Germany generics market value forecast: $ million, 2024-29
Table 30: Germany generics market volume forecast: % of total pharma volume, 2024-29
Table 31: Germany Size of Population (Million), 2020-24
Table 32: Germany Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 33: Germany GDP (Current Prices, $ Billion), 2020-24
Table 34: Germany Inflation, 2020-24
Table 35: Germany Consumer Price Index (Absolute), 2020-24
Table 36: Germany Exchange Rate, 2019-24
Table 37: Italy generics market value: $ million, 2019-24
Table 38: Italy generics market volume: % of total pharma volume, 2019-24
Table 39: Italy generics market geography segmentation: $ million, 2024
Table 40: Italy generics market value forecast: $ million, 2024-29
Table 41: Italy generics market volume forecast: % of total pharma volume, 2024-29
Table 42: Italy Size of Population (Million), 2020-24
Table 43: Italy Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 44: Italy GDP (Current Prices, $ Billion), 2020-24
Table 45: Italy Inflation, 2020-24
Table 46: Italy Consumer Price Index (Absolute), 2020-24
Table 47: Italy Exchange Rate, 2019-24
Table 48: Japan generics market value: $ million, 2019-24
Table 49: Japan generics market volume: % of total pharma volume, 2019-24
Table 50: Japan generics market geography segmentation: $ million, 2024
Table 51: Japan generics market value forecast: $ million, 2024-29
Table 52: Japan generics market volume forecast: % of total pharma volume, 2024-29
Table 53: Japan Size of Population (Million), 2020-24
Table 54: Japan Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 55: Japan GDP (Current Prices, $ Billion), 2020-24
Table 56: Japan Inflation, 2020-24
Table 57: Japan Consumer Price Index (Absolute), 2020-24
Table 58: Japan Exchange Rate, 2019-24
Table 59: Russia generics market value: $ million, 2019-24
Table 60: Russia generics market volume: % of total pharma volume, 2019-24
Table 61: Russia generics market geography segmentation: $ million, 2024
Table 62: Russia generics market value forecast: $ million, 2024-29
Table 63: Russia generics market volume forecast: % of total pharma volume, 2024-29
Table 64: Russia Size of Population (Million), 2020-24
Table 65: Russia Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 66: Russia GDP (Current Prices, $ Billion), 2020-24
Table 67: Russia Inflation, 2020-24
Table 68: Russia Consumer Price Index (Absolute), 2020-24
Table 69: Russia Exchange Rate, 2019-24
Table 70: United Kingdom generics market value: $ million, 2019-24
Table 71: United Kingdom generics market volume: % of total pharma volume, 2019-24
Table 72: United Kingdom generics market geography segmentation: $ million, 2024
Table 73: United Kingdom generics market value forecast: $ million, 2024-29
Table 74: United Kingdom generics market volume forecast: % of total pharma volume, 2024-29
Table 75: United Kingdom Size of Population (Million), 2020-24
Table 76: United Kingdom Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 77: United Kingdom GDP (Current Prices, $ Billion), 2020-24
Table 78: United Kingdom Inflation, 2020-24
Table 79: United Kingdom Consumer Price Index (Absolute), 2020-24
Table 80: United Kingdom Exchange Rate, 2019-24
Table 81: United States generics market value: $ million, 2019-24
Table 82: United States generics market volume: % of total pharma volume, 2019-24
Table 83: United States generics market geography segmentation: $ million, 2024
Table 84: United States generics market value forecast: $ million, 2024-29
Table 85: United States generics market volume forecast: % of total pharma volume, 2024-29
Table 86: United States Size of Population (Million), 2020-24
Table 87: United States Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 88: United States GDP (Current Prices, $ Billion), 2020-24
Table 89: United States Inflation, 2020-24
Table 90: United States Consumer Price Index (Absolute), 2020-24
Table 91: United States Exchange Rate, 2019-24
Table 92: Sun Pharmaceutical Industries Ltd: Key Facts
Table 93: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 94: Sun Pharmaceutical Industries Ltd: Key Employees
Table 95: Viatris Inc: Key Facts
Table 96: Viatris Inc: Annual Financial Ratios
Table 97: Viatris Inc: Key Employees
Table 98: Novartis AG: Key Facts
Table 99: Novartis AG: Annual Financial Ratios
Table 100: Novartis AG: Key Employees
Table 101: Teva Pharmaceutical Industries Ltd: Key Facts
Table 102: Teva Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 103: Teva Pharmaceutical Industries Ltd: Key Employees
Table 104: Sandoz Group AG: Key Facts
Table 105: Sandoz Group AG: Annual Financial Ratios
Table 106: Sandoz Group AG: Key Employees
Table 107: Hikma Pharmaceuticals Plc: Key Facts
Table 108: Hikma Pharmaceuticals Plc: Annual Financial Ratios
Table 109: Hikma Pharmaceuticals Plc: Key Employees
Table 110: Sanofi: Key Facts
Table 111: Sanofi: Annual Financial Ratios
Table 112: Sanofi: Key Employees
Table 113: Sanofi: Key Employees Continued
Table 114: Les Laboratoires Servier SAS: Key Facts
Table 115: Les Laboratoires Servier SAS: Key Employees
Table 116: Stada Arzneimittel AG: Key Facts
Table 117: Stada Arzneimittel AG: Key Employees
Table 118: Bayer AG: Key Facts
Table 119: Bayer AG: Annual Financial Ratios
Table 120: Bayer AG: Key Employees
Table 121: Bayer AG: Key Employees Continued
Table 122: Bayer AG: Key Employees Continued
Table 123: Lupin Ltd: Key Facts
Table 124: Lupin Ltd: Annual Financial Ratios
Table 125: Lupin Ltd: Key Employees
Table 126: Aspen Pharmacare Holdings Ltd: Key Facts
Table 127: Aspen Pharmacare Holdings Ltd: Annual Financial Ratios
Table 128: Aspen Pharmacare Holdings Ltd: Key Employees
Table 129: EMS SA: Key Facts
Table 130: EMS SA: Key Employees
Table 131: Eurofarma Laboratorios SA: Key Facts
Table 132: Eurofarma Laboratorios SA: Key Employees
Table 133: Ache Laboratorios Farmaceuticos SA: Key Facts
Table 134: Ache Laboratorios Farmaceuticos SA: Key Employees
Table 135: Sino Biopharmaceutical Ltd: Key Facts
Table 136: Sino Biopharmaceutical Ltd: Annual Financial Ratios
Table 137: Sino Biopharmaceutical Ltd: Key Employees
Table 138: Hansoh Pharmaceutical Group Co Ltd: Key Facts
Table 139: Hansoh Pharmaceutical Group Co Ltd: Annual Financial Ratios
Table 140: Hansoh Pharmaceutical Group Co Ltd: Key Employees
Table 141: CSPC Pharmaceutical Group Ltd: Key Facts
Table 142: CSPC Pharmaceutical Group Ltd: Annual Financial Ratios
Table 143: CSPC Pharmaceutical Group Ltd: Key Employees
Table 144: Dr. Reddy's Laboratories Ltd: Key Facts
Table 145: Dr. Reddy's Laboratories Ltd: Annual Financial Ratios
Table 146: Dr. Reddy's Laboratories Ltd: Key Employees
Table 147: Cipla Ltd: Key Facts
Table 148: Cipla Ltd: Annual Financial Ratios
Table 149: Cipla Ltd: Key Employees
Table 150: Aurobindo Pharma Ltd: Key Facts
Table 151: Aurobindo Pharma Ltd: Annual Financial Ratios
Table 152: Aurobindo Pharma Ltd: Key Employees
Table 153: Aurobindo Pharma Ltd: Key Employees Continued
Table 154: PT Indofarma Tbk: Key Facts
Table 155: PT Indofarma Tbk: Annual Financial Ratios
Table 156: PT Sanbe Farma: Key Facts
Table 157: PT Sanbe Farma: Key Employees
Table 158: PT Kalbe Farma Tbk: Key Facts
Table 159: PT Kalbe Farma Tbk: Annual Financial Ratios
Table 160: PT Kalbe Farma Tbk: Key Employees
Table 161: PT Soho Global Health Tbk: Key Facts
Table 162: PT Soho Global Health Tbk: Annual Financial Ratios
Table 163: PT Soho Global Health Tbk: Key Employees
Table 164: Friulchem SpA: Key Facts
Table 165: Friulchem SpA: Key Employees
Table 166: DOC Generici SRL: Key Facts
Table 167: DOC Generici SRL: Key Employees
Table 168: Recordati SpA: Key Facts
Table 169: Recordati SpA: Annual Financial Ratios
Table 170: Recordati SpA: Key Employees
Table 171: Daiichi Sankyo Co Ltd: Key Facts
Table 172: Daiichi Sankyo Co Ltd: Annual Financial Ratios
Table 173: Daiichi Sankyo Co Ltd: Key Employees
Table 174: Daiichi Sankyo Co Ltd: Key Employees Continued
Table 175: Sawai Group Holdings Co Ltd: Key Facts
Table 176: Sawai Group Holdings Co Ltd: Annual Financial Ratios
Table 177: Sawai Group Holdings Co Ltd: Key Employees
Table 178: Toho Holdings Co Ltd: Key Facts
Table 179: Toho Holdings Co Ltd: Annual Financial Ratios
Table 180: Toho Holdings Co Ltd: Key Employees
Table 181: Towa Pharmaceutical Co Ltd: Key Facts
Table 182: Towa Pharmaceutical Co Ltd: Annual Financial Ratios
Table 183: Towa Pharmaceutical Co Ltd: Key Employees
Table 184: Towa Pharmaceutical Co Ltd: Key Employees Continued
Table 185: Laboratorios Silanes SA de CV: Key Facts
Table 186: Pfizer Inc: Key Facts
Table 187: Pfizer Inc: Annual Financial Ratios
Table 188: Pfizer Inc: Key Employees
Table 189: Pfizer Inc: Key Employees Continued
Table 190: Bluefish Pharmaceuticals AB: Key Facts
Table 191: Bluefish Pharmaceuticals AB: Key Employees
Table 192: AstraZeneca Plc: Key Facts
Table 193: AstraZeneca Plc: Annual Financial Ratios
Table 194: AstraZeneca Plc: Key Employees
Table 195: Navamedic ASA: Key Facts
Table 196: Navamedic ASA: Annual Financial Ratios
Table 197: Navamedic ASA: Key Employees
Table 198: Beacons Pharmaceuticals Pte Ltd: Key Facts
Table 199: Abbott Laboratories SA: Key Facts
Table 200: Adcock Ingram Holdings Ltd: Key Facts
Table 201: Adcock Ingram Holdings Ltd: Key Employees
Table 202: Dongkook Pharmaceutical Co Ltd: Key Facts
Table 203: Dongkook Pharmaceutical Co Ltd: Annual Financial Ratios
Table 204: Dongkook Pharmaceutical Co Ltd: Key Employees
Table 205: JW Holdings Corp: Key Facts
Table 206: JW Holdings Corp: Annual Financial Ratios
Table 207: JW Holdings Corp: Key Employees
Table 208: Hanmi Pharmaceuticals Co Ltd: Key Facts
Table 209: Hanmi Pharmaceuticals Co Ltd: Annual Financial Ratios
Table 210: Hanmi Pharmaceuticals Co Ltd: Key Employees
Table 211: Dong Wha Pharma Co Ltd: Key Facts
Table 212: Dong Wha Pharma Co Ltd: Annual Financial Ratios
Table 213: Dong Wha Pharma Co Ltd: Key Employees
Table 214: Esteve Pharmaceuticals SA: Key Facts
Table 215: Esteve Pharmaceuticals SA: Key Employees
Table 216: Abdi Ibrahim Ilac Sanayi ve Ticaret AS: Key Facts
Table 217: Abdi Ibrahim Ilac Sanayi ve Ticaret AS: Key Employees
Table 218: Deva Holding AS: Key Facts
Table 219: Deva Holding AS: Annual Financial Ratios
Table 220: Deva Holding AS: Key Employees
Table 221: Apotex Inc: Key Facts
Table 222: Apotex Inc: Key Employees
Table 223: Pharmstandard: Key Facts
Table 224: Pharmstandard: Key Employees
Table 225: Biocad: Key Facts
Table 226: Biocad: Key Employees
Table 227: R-Pharm: Key Facts
Table 228: R-Pharm: Key Employees
List of Figures
Figure 1: G8 generics industry, revenue($m), 2020-29
Figure 2: G8 Generics industry, revenue by country (%), 2024
Figure 3: G8 generics industry, revenue by country ($m), 2020-24
Figure 4: G8 generics industry forecast, revenue by country ($m), 2024-29
Figure 5: Canada generics market value: $ million, 2019-24
Figure 6: Canada generics market volume: % of total pharma volume, 2019-24
Figure 7: Canada generics market geography segmentation: % share, by value, 2024
Figure 8: Canada generics market value forecast: $ million, 2024-29
Figure 9: Canada generics market volume forecast: % of total pharma volume, 2024-29
Figure 10: Forces driving competition in the generics market in Canada, 2024
Figure 11: Drivers of buyer power in the generics market in Canada, 2024
Figure 12: Drivers of supplier power in the generics market in Canada, 2024
Figure 13: Factors influencing the likelihood of new entrants in the generics market in Canada, 2024
Figure 14: Factors influencing the threat of substitutes in the generics market in Canada, 2024
Figure 15: Drivers of degree of rivalry in the generics market in Canada, 2024
Figure 16: France generics market value: $ million, 2019-24
Figure 17: France generics market volume: % of total pharma volume, 2019-24
Figure 18: France generics market geography segmentation: % share, by value, 2024
Figure 19: France generics market value forecast: $ million, 2024-29
Figure 20: France generics market volume forecast: % of total pharma volume, 2024-29
Figure 21: Forces driving competition in the generics market in France, 2024
Figure 22: Drivers of buyer power in the generics market in France, 2024
Figure 23: Drivers of supplier power in the generics market in France, 2024
Figure 24: Factors influencing the likelihood of new entrants in the generics market in France, 2024
Figure 25: Factors influencing the threat of substitutes in the generics market in France, 2024
Figure 26: Drivers of degree of rivalry in the generics market in France, 2024
Figure 27: Germany generics market value: $ million, 2019-24
Figure 28: Germany generics market volume: % of total pharma volume, 2019-24
Figure 29: Germany generics market geography segmentation: % share, by value, 2024
Figure 30: Germany generics market value forecast: $ million, 2024-29
Figure 31: Germany generics market volume forecast: % of total pharma volume, 2024-29
Figure 32: Forces driving competition in the generics market in Germany, 2024
Figure 33: Drivers of buyer power in the generics market in Germany, 2024
Figure 34: Drivers of supplier power in the generics market in Germany, 2024
Figure 35: Factors influencing the likelihood of new entrants in the generics market in Germany, 2024
Figure 36: Factors influencing the threat of substitutes in the generics market in Germany, 2024
Figure 37: Drivers of degree of rivalry in the generics market in Germany, 2024
Figure 38: Italy generics market value: $ million, 2019-24
Figure 39: Italy generics market volume: % of total pharma volume, 2019-24
Figure 40: Italy generics market geography segmentation: % share, by value, 2024
Figure 41: Italy generics market value forecast: $ million, 2024-29
Figure 42: Italy generics market volume forecast: % of total pharma volume, 2024-29
Figure 43: Forces driving competition in the generics market in Italy, 2024
Figure 44: Drivers of buyer power in the generics market in Italy, 2024
Figure 45: Drivers of supplier power in the generics market in Italy, 2024
Figure 46: Factors influencing the likelihood of new entrants in the generics market in Italy, 2024
Figure 47: Factors influencing the threat of substitutes in the generics market in Italy, 2024
Figure 48: Drivers of degree of rivalry in the generics market in Italy, 2024
Figure 49: Japan generics market value: $ million, 2019-24
Figure 50: Japan generics market volume: % of total pharma volume, 2019-24
Figure 51: Japan generics market geography segmentation: % share, by value, 2024
Figure 52: Japan generics market value forecast: $ million, 2024-29
Figure 53: Japan generics market volume forecast: % of total pharma volume, 2024-29
Figure 54: Forces driving competition in the generics market in Japan, 2024
Figure 55: Drivers of buyer power in the generics market in Japan, 2024
Figure 56: Drivers of supplier power in the generics market in Japan, 2024
Figure 57: Factors influencing the likelihood of new entrants in the generics market in Japan, 2024
Figure 58: Factors influencing the threat of substitutes in the generics market in Japan, 2024
Figure 59: Drivers of degree of rivalry in the generics market in Japan, 2024
Figure 60: Russia generics market value: $ million, 2019-24
Figure 61: Russia generics market volume: % of total pharma volume, 2019-24
Figure 62: Russia generics market geography segmentation: % share, by value, 2024
Figure 63: Russia generics market value forecast: $ million, 2024-29
Figure 64: Russia generics market volume forecast: % of total pharma volume, 2024-29
Figure 65: Forces driving competition in the generics market in Russia, 2024
Figure 66: Drivers of buyer power in the generics market in Russia, 2024
Figure 67: Drivers of supplier power in the generics market in Russia, 2024
Figure 68: Factors influencing the likelihood of new entrants in the generics market in Russia, 2024
Figure 69: Factors influencing the threat of substitutes in the generics market in Russia, 2024
Figure 70: Drivers of degree of rivalry in the generics market in Russia, 2024
Figure 71: United Kingdom generics market value: $ million, 2019-24
Figure 72: United Kingdom generics market volume: % of total pharma volume, 2019-24
Figure 73: United Kingdom generics market geography segmentation: % share, by value, 2024
Figure 74: United Kingdom generics market value forecast: $ million, 2024-29
Figure 75: United Kingdom generics market volume forecast: % of total pharma volume, 2024-29
Figure 76: Forces driving competition in the generics market in the United Kingdom, 2024
Figure 77: Drivers of buyer power in the generics market in the United Kingdom, 2024
Figure 78: Drivers of supplier power in the generics market in the United Kingdom, 2024
Figure 79: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2024
Figure 80: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2024
Figure 81: Drivers of degree of rivalry in the generics market in the United Kingdom, 2024
Figure 82: United States generics market value: $ million, 2019-24
Figure 83: United States generics market volume: % of total pharma volume, 2019-24
Figure 84: United States generics market geography segmentation: % share, by value, 2024
Figure 85: United States generics market value forecast: $ million, 2024-29
Figure 86: United States generics market volume forecast: % of total pharma volume, 2024-29
Figure 87: Forces driving competition in the generics market in the United States, 2024
Figure 88: Drivers of buyer power in the generics market in the United States, 2024
Figure 89: Drivers of supplier power in the generics market in the United States, 2024
Figure 90: Factors influencing the likelihood of new entrants in the generics market in the United States, 2024
Figure 91: Factors influencing the threat of substitutes in the generics market in the United States, 2024
Figure 92: Drivers of degree of rivalry in the generics market in the United States, 2024
